Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer

被引:20
|
作者
Jeremic, B
Shibamoto, Y
机构
[1] KYOTO UNIV, CHEST DIS RES INST, DEPT ONCOL, KYOTO 60601, JAPAN
[2] UNIV HOSP, DEPT ONCOL, KRAGUJEVAC, YUGOSLAVIA
关键词
radiotherapy; hyperfractionation; interfraction interval; nonsmall cell lung cancer;
D O I
10.1016/0360-3016(95)02158-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore the influence of interfraction interval in hyperfractionated radiotherapy (HFX RT) with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer. Methods and Materials: One hundred sixty-nine patients treated in a randomized study were retrospectively analyzed. Group I patients were treated by HFX RT with 1.2 Gy twice daily with a total dose of 64.8 Gy in 27 treatment days, while Groups II and III patients were treated by the same HFX RT and concurrent chemotherapy with carboplatin and etoposide (every week in Group II and every other week in Group III). Interfraction intervals of either 4.5-5 h or 5.5-6 h were used for each patient. Results: Patients treated with shorter interfraction intervals (4.5-5 h) had a better prognosis than those treated with longer intervals (5.5-6 h)(median survival: 22 vs. 7 months; 5-year survival rate: 27% vs. 0%, p = 0.00000). This phenomenon was observed in all treatment groups. Patients greater than or equal to 60 years of age, with Stage IIIA disease, or with previous weight loss less than or equal to 5% were treated more often with the shorter intervals than those < 60 years, with Stage IIIB disease, or with weight loss > 5%, respectively, but in all of these subgroups of patients, the shorter intervals were associated with a better prognosis. Multivariate analysis showed that the interfraction interval was an independent prognostic factor, together with sex, age, performance status, and stage, The shorter intervals were associated with an increased incidence of acute high grade toxicity, but not with an increase in late toxicity. Conclusion: Patients treated with shorter interfraction intervals (4.5-5 h) appeared to have a better survival than those treated with longer intervals (5.5-6 h). Prospective randomized studies are warranted to further investigate the influence of interfraction interval in HFX RT.
引用
收藏
页码:303 / 308
页数:6
相关论文
共 50 条
  • [1] Influence of interfraction interval on the efficacy and toxicity of hyperfractionated radiotherapy in combination with concurrent daily chemotherapy in stage III non-small-cell lung cancer
    Shibamoto, Y
    Jeremic, B
    Acimovic, L
    Milicic, B
    Nikolic, N
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (02): : 295 - 300
  • [2] Interfraction interval in patients with stage III non-small-cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy - Final results in 536 patients
    Jeremic, B
    Milicic, B
    Dagovic, A
    Aleksandrovic, J
    Milisavljevic, S
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (06): : 616 - 625
  • [3] Absence of thoracic radiation myelitis after hyperfractionated radiation therapy with and without concurrent chemotherapy for stage III nonsmall-cell lung cancer
    Jeremic, B
    Shibamoto, Y
    Milicic, B
    Acimovic, L
    Milisavljevic, S
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 40 (02): : 343 - 346
  • [5] Clinical Prognostic Factors in Patients With Locally Advanced (Stage III) Nonsmall Cell Lung Cancer Treated With Hyperfractionated Radiation Therapy With and Without Concurrent Chemotherapy
    Jeremic, Branislav
    Milicic, Biljana
    Milisavljevic, Slobodan
    CANCER, 2011, 117 (13) : 2995 - 3003
  • [6] HYPERFRACTIONATED RADIATION-THERAPY WITH AND WITHOUT CONCURRENT CHEMOTHERAPY FOR ADVANCED NONSMALL CELL LUNG-CANCER
    JEREMIC, B
    JEVREMOVIC, S
    MIJATOVIC, L
    MILISAVLJEVIC, S
    CANCER, 1993, 71 (11) : 3732 - 3736
  • [7] Hyperfractionated radiotherapy alone for clinical stage I nonsmall cell lung cancer
    Jeremic, B
    Shibamoto, Y
    Acimovic, L
    Milisavljevic, S
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 38 (03): : 521 - 525
  • [8] Hyperfractionated 3D conformal radiotherapy and concurrent chemotherapy for unresectable stage III non-small cell lung cancer
    Choi, EK
    Ahn, SD
    Yi, BY
    Chang, HS
    Lee, JH
    Suh, CW
    Lee, JS
    Kim, SH
    Koh, YS
    Kim, WS
    Kim, DS
    Kim, WD
    Sohn, KH
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (02): : 313 - 313
  • [9] Pretreatment prognostic factors in stage III non-small cell lung cancer (NSCLC) treated with hyperfractionated radiotherapy (HFX RT) with and without concurrent chemotherapy (CHT)
    Jeremic, B
    Shibamoto, Y
    Acimovic, L
    Milisavljevic, S
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1051 - 1051
  • [10] Concurrent cisplatin-vindesine and hyperfractionated thoracic radiotherapy in locally advanced nonsmall cell lung cancer
    LePechoux, C
    Arriagada, R
    LeChevalier, T
    Bretel, JJ
    Cosset, BP
    Ruffie, P
    Baldeyrou, P
    Grunenwald, D
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (03): : 519 - 525